



**VIETNAM VETERINARY PRODUCTS
JOINT STOCK COMPANY I
(VINAVETCO)**

SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom – Happiness

**PROGRAMME ANNUAL GENERAL MEETING OF SHAREHOLDERS 2026
VIETNAM VETERINARY PRODUCTS JOINT STOCK COMPANY I**

- + **Time to welcome and check shareholder status:** From 7:30 to 8:00 Saturday, May 16, 2026
- + **Expected meeting time:** From 8:00 to 12:30, Saturday, May 16, 2026
- + **Address: Central Veterinary Company Limited 1:** Address: At Binh Luong Hamlet, Nhu Quynh Commune, Hung Yen Province

Time	The main contents of the meeting
I	CONGRESS OPENING PROCEDURES
7:30 – 8:00	<ul style="list-style-type: none">- Welcoming, registering delegates and distributing documents
8:00 – 8:30	<ul style="list-style-type: none">- Opening, declaring the reason, introducing delegates and guests- Announcing the decision to establish the Shareholder Qualification Examination Committee- Announcing the results of the shareholder qualification examination- Approving the Presidium- Approving the Secretariat- Approving the Ballot Counting Committee- Approving the Agenda and Regulations of the Congress
II	REPORTS AND SUBMISSIONS
8:30 – 9:45	<ul style="list-style-type: none">- Report on the activities of the Board of Directors of the Company in 2025, and orientation for 2026.- Report of the Audit Committee in 2025 <p>CONTENTS OF THE PRESENTATION TABLES:</p> <ol style="list-style-type: none">1. Submission : Report of the Board of Directors2. Submission : Approval of the Audit Committee's Report3. Submission : Approval of the Audited Financial Report for 20254. Submission : Profit distribution plan for 20255. Submission : Approval of remuneration of the Board of Directors, Audit Committee, and Corporate Governance



Time	The main contents of the meeting
	6. Submission : Approval of the Selection of an Audit firm for the 2026 Financial Statements
	7. Other issues.
III	DISCUSS
9:45 – 10:20	- <i>Shareholders participate in giving opinions, discussing and answering questions from the Presidium</i>
IV	VOTING ON CONGRESS PROPOSALS
10:20-10:35	- <i>Discuss and vote to approve reports and proposals</i> - <i>Approve the election regulations and election instructions</i> - <i>Other issues.</i>
V	BREAK AND VOTE COUNTING
10:35– 11:15	- <i>Shareholders take a break;</i> - <i>Voting on issues at the General Meeting.</i>
IV	END OF CONGRESS
11:15-12:00	- <i>Announcement of the Minutes of the vote counting</i>
	- <i>Approval of the Minutes and Resolution of the General Meeting of Shareholders</i>
	- <i>Declaration of the closing of the General Meeting</i>





VIETNAM VETERINARY PRODUCTS JOINT STOCK COMPANY I

Head Office Address: No. 88 Truong Chinh Street, Kim Lien Ward,
Hanoi City
Phone Number : 0243.8691262 | Fax: 0243.8691263
Email: info@vinavetco.com | Website: vinavetco.com

INVITATION LETTER TO THE ANNUAL GENERAL MEETING OF SHAREHOLDERS 2026 *Vietnam Veterinary Products Joint Stock Company I*

Name of Shareholder:

Custodian Code::

Personal information:

umber of shares owned:

Address :



The Board of Directors of Vietnam Veterinary Products Joint Stock Company “VINAVETCO” would like to invites our respected Shareholders with the follows information to attend the 2026 Annual General Meeting of Shareholders (the “VNY”)

1. Time to welcome and check shareholder status: From 7:30 to 8:00 Saturday, May 16, 2026

2. Expected meeting time: From 8:00 to 12:30, Saturday, May 16, 2026

Address: Central Veterinary Company Limited 1: Address: At Binh Luong Hamlet, Nhu Quynh Commune, Hung Yen Province

3. The main contents of the meeting: The Annual General Meeting of Shareholders will discuss and approve the following items:

- Annual general meeting of shareholders 2026
- Other issues under the authority of the General Meeting of Shareholders (if any).

4. Members Attending the Meeting : All shareholders owning shares in the Company (or their legally authorized representatives) according to the shareholder list as of April 14, 2026, compiled by the Vietnam Securities Depository and Clearing Corporation.

Meeting documents: To view meeting documents and details of the General Meeting, shareholders can visit the Company's website at: <http://www.vinavetco.com>

5. Registration to attend the Congress: In order to prepare for the Congress and welcome shareholders carefully, the Board of Directors of the Company respectfully

requests that shareholders confirm their attendance before 4:30 p.m. on May 12, 2026 in the following forms

- Send or fax the Attendance Confirmation (according to the form attached to the Invitation) to the Company:

+ Address: 88 Truong Chinh, Phuong Mai, Dong Da, Hanoi.

+ Fax number: 024 38691263

+ Call to confirm attendance to the phone number: 024 38691262 + Hotline 0988286335

6. Other issues:

- Shareholders who do not attend in person can authorize another person to attend according to the attached Authorization Form.

- Shareholders or authorized persons attending the General Meeting, please bring the Meeting Invitation, valid ID card/CCCD card/Passport, Authorization Letter, according to the regulations on authorization to attend the General Meeting of Shareholders of Central Vietnam Veterinary Products Joint Stock Company I (in case of receiving authorization to attend the General Meeting).

- All travel, accommodation and other expenses during the General Meeting of Shareholders shall be paid by the attendees.

- All comments and contributions to the content of the General Meeting, Shareholders shall send in writing to the Company before 4:30 p.m. on May 12, 2026

We are pleased to welcome you, Shareholders, to the 2026 Annual General Meeting of Shareholders of Central Vietnam Veterinary Products Joint Stock Company I

Yours sincerely!

Attached documents:

- Congress program;
- Congress attendance confirmation;
- Congress attendance authorization.

Hanoi, April 19, 2026
ON BEHALF OF THE BOARD OF
DIRECTORS
chairman of the board of directors



Nguyen Anh Tuan



SOCIALIST REPUBLIC OF VIETNAM

Independence - Freedom – Happiness

---***---

POWER OF ATTORNEY

ANNUAL GENERAL MEETING OF SHAREHOLDERS 2026

To: Vietnam Veterinary Products Joint Stock Company I

1. Authorized party

Shareholder name (individual/organization):

ID card/CCCD/HC/MSDN number:

Date of issue:

Place of issue:

Address:

Legal representative of the shareholder being an organization:.....

Number of shares owned: (In words:)

Number of authorized shares: (In words:)

2. Authorized party:

2.1 Name of individual/organization:.....

ID card/CCCD/HC/DKKD number:Date of issue:Place of issue:

Address:

Representative:

ID card/CCCD/HC/DKKD number:Date of issue:Place of issue:.....

2.2 Authorize one of the members of the Board of Directors of Central Vietnam Veterinary Products Joint Stock Company I by checking one of the boxes below:

☐ Mr. Nguyen Anh Tuan - Chairman of the Board of Directors

☐ Bà: Tran Thi Bich Ngoc - Member of the Board of Directors

☐ Mr. Nguyen Viet Hoang - Independent Member of the Board of Directors

3. Authorization content:

The authorized party is authorized to represent the authorized party to attend the 2026 Annual General Meeting of Shareholders of Central Vietnam Veterinary Products Joint Stock Company I and to exercise all rights and obligations of Shareholders at the 2026 Annual General Meeting of Shareholders within the scope of authorized shares.

We are fully responsible for this authorization and commit to strictly comply with current provisions of the Law and the Charter of organization and operation of Central Vietnam Veterinary Products Joint Stock Company I This authorization is effective from the date of signing until the completion of the above authorized content. The authorized party is not allowed to re-authorize to another person.

....., date ... month ... year 2026

BEING AUTHORIZED

(Sign, confirm full name and seal)

AUTHORIZING

(Sign, confirm full name and seal)

When attending the General Meeting of Shareholders, the Authorized Party must provide:

- Invitation letter;

- Original copy of this Authorization Letter;

- Present the original ID card/CCCD/HC of the Authorized Party



SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom – Happiness
---***---

CONFIRMATION OF ATTENDANCE
ANNUAL GENERAL MEETING OF SHAREHOLDERS 2026

To: *Vietnam Veterinary Products Joint Stock Company I*

Shareholder name (individual/organization):.....
ID card/CCCD/HC/MSDN number: Date of issue:..... Place of issue:.....
Address:
Legal representative of the shareholder being an organization:.....
Number of shares owned: (In words:)

Pursuant to the Invitation to the 2026 Annual General Meeting of Shareholders of Vietnam

Veterinary Products Joint Stock Company I, we/we hereby confirm as follows (check one of the two boxes below):

☐ Attend in person the 2026 Annual General Meeting of Shareholders of Central Veterinary Products Joint Stock Company I.

☐ Authorize another person to attend the 2026 Annual General Meeting of Shareholders of Central Veterinary Products Joint Stock Company I (with a Power of Attorney in the form sent or faxed to Central Veterinary Products Joint Stock Company I).

Yours sincerely!

....., date ... month ... year 2026
SHAREHOLDERS
(Sign, confirm full name and seal)

Hanoi, April 16, 2026

SUBMISSION

Re: Through the Report of the Board of Directors

**TO : The 2025 Annual General Meeting of Shareholders of Central Veterinary
products Joint Stock Company I**

- Pursuant to Law on Enterprises No. 59/2020/QH14 dated June 17, 2020; and implementing documents;*
- Pursuant to the Charter of organization and operation of Central Veterinary products Joint Stock Company I.*

**The Board of Directors respectfully submits to the General Meeting of Shareholders for
consideration and approval the following contents:**

Report on the Company's Board of Directors' activities in 2025 and orientation for 2026;

Respectfully submit to the Company's General Meeting of Shareholders for consideration
and approval.

Yours sincerely!

**ON BEHALF OF THE BOARD OF
DIRECTORS**

chairman of the board of directors



NGUYEN ANH TUAN

**VIETNAM VETERINARY
PRODUCTS JOINT STOCK
COMPANY I**

(VINAVETCO)

No: 18 -2026 /TTr-ĐHĐCĐ

SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom – Happiness

Hanoi, April 16, 2026

SUBMISSION

Re: Approval of the Audit Committee's Report

TO : The 2026 Annual General Meeting of Shareholders of Central Veterinary products Joint Stock Company I

- Pursuant to Law on Enterprises No. 59/2020/QH14 dated June 17, 2020; and implementing documents;
- Pursuant to the Charter of organization and operation of Central Veterinary products Joint Stock Company I.

**The Board of Directors respectfully submits to the General Meeting of Shareholders
for consideration and approval the following contents:**

Audit Committee's performance report in 2025 and Audit Committee's task implementation plan in 2026

Respectfully submit to the Company's General Meeting of Shareholders for consideration and approval.

Yours sincerely!

**ON BEHALF OF THE BOARD OF
DIRECTORS**

chairman of the board of directors



NGUYEN ANH TUAN

**VIETNAM VETERINARY
PRODUCTS JOINT STOCK
COMPANY I**

(VINA VETCO)

No: 19 -2026 /TTr-ĐHĐCĐ

**SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom – Happiness**

Hanoi, April 16, 2026

SUBMISSION

Re: Approval of the Audited Financial Report for 2025

**TO : The 2026 Annual General Meeting of Shareholders of Central Veterinary
products Joint Stock Company I**

- Pursuant to Law on Enterprises No. 59/2020/QH14 dated June 17, 2020; and implementing documents;
- Pursuant to the Charter of organization and operation of Central Veterinary products Joint Stock Company I.

**The Board of Directors respectfully submits to the General Meeting of Shareholders for
consideration and approval the following contents:**

Approving the 2025 audited financial statements of Central Veterinary Medicine Joint Stock Company I, independently audited by UHY Auditing and Consulting LLC, signed on March 25, 2026.

Respectfully submit to the Company's General Meeting of Shareholders for consideration and approval.

Yours sincerely!

**ON BEHALF OF THE BOARD OF
DIRECTORS**
chairman of the board of directors



NGUYEN ANH TUAN

Hanoi, April 16, 2026

SUBMISSION

Re: Profit distribution plan for 2025

TO : The 2026 Annual General Meeting of Shareholders of Central Veterinary products Joint Stock Company I

- Pursuant to Law on Enterprises No. 59/2020/QH14 dated June 17, 2020; and implementing documents;
- Pursuant to the Charter of organization and operation of Central Veterinary products Joint Stock Company I.

The Board of Directors respectfully submits to the General Meeting of Shareholders for consideration and approval the following contents:

1. Profit distribution in 2025: No dividend payment.
2. The 2026 profit distribution will be decided by the 2027 Annual General Meeting of Shareholders based on the Company's 2026 production and business results after fulfilling its obligations to the State budget and other financial obligations as prescribed by law.

Respectfully submit to the Company's General Meeting of Shareholders for consideration and approval.

Yours sincerely!

**ON BEHALF OF THE BOARD OF
DIRECTORS**
chairman of the board of directors



NGUYEN ANH TUAN

Hanoi, April 16, 2026

SUBMISSION

Re: Approval of remuneration of the Board of Directors, Audit Committee, and Corporate Governance

TO : The 2025 Annual General Meeting of Shareholders of Central Veterinary products Joint Stock Company I

- Pursuant to Law on Enterprises No. 59/2020/QH14 dated June 17, 2020; and implementing documents;
- Pursuant to the Charter of organization and operation of Central Veterinary products Joint Stock Company I.

The Board of Directors respectfully submits to the General Meeting of Shareholders for consideration and approval the following contents:

1. The final settlement of remuneration of the Board of Directors and the Audit Committee in 2025 according to Resolution No. 18-2025/NQ-ĐHĐCĐ dated April 26, 2025 of the General Meeting of Shareholders is as follows:

- Remuneration paid to the Board of Directors is: VND 108,000,000

2. Proposed remuneration for members of the Board of Directors and Audit Committee in 2026 as follows:

- Chairman of the Board of Directors: VND 3,000,000/month

- Member of the Board of Directors: VND 2,000,000/month

- Company Administrator: VND 2,000,000/month

Respectfully submit to the Company's General Meeting of Shareholders for consideration and approval.

Yours sincerely!

**ON BEHALF OF THE BOARD OF
DIRECTORS**

chairman of the board of directors



NGUYEN ANH TUAN

**VIETNAM VETERINARY
PRODUCTS JOINT STOCK
COMPANY I**

(VINA VETCO)

No: 22 -2026 /TTr-DHĐCĐ

**SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom – Happiness**

Hanoi, April 16, 2026

SUBMISSION

(Re: Approval of the Selection of an Audit firm for the 2026 Financial Statements)

**TO : The 2026 Annual General Meeting of Shareholders of Central Veterinary
products Joint Stock Company I**

- Pursuant to Law on Enterprises No. 59/2020/QH14 dated June 17, 2020; and implementing documents;
- Pursuant to the Charter of organization and operation of Central Veterinary products Joint Stock Company I.

The Audit Committee respectfully submits to the Company's General Meeting of Shareholders for consideration and approval of the following content:

To ensure proactive selection of a suitable auditing unit, meeting the Company's requirements on implementation time and service quality, the Audit Committee respectfully requests the General Meeting of Shareholders to authorize the Audit Committee to select an auditing company listed in the list of independent auditing companies qualified to audit according to current regulations to conduct the audit of the semi-annual financial statements for 2026 and the financial statements for 2026 (Quarterly financial statements can be reviewed if necessary at the request of the State management agency). Respectfully submit to the Company's General Meeting of Shareholders for consideration and approval.

Yours sincerely!

**INDEPENDENT MEMBER OF THE BOARD OF DIRECTORS
Chairman of the Audit Committee**



NGUYEN VIET HOANG

Hung Yen, May 16, 2026

DỰ THẢO

REPORT OF THE AUDIT COMMITTEE
VIETNAM VETERINARY PRODUCTS JOINT STOCK COMPANY I

(Presented to the Annual General Meeting of Shareholders 2026)

Dear Shareholders and Distinguished Delegates.

- Based on the Charter and operational regulations of the Vietnam Veterinary Products Joint Stock Company I

In performing its assigned functions and duties, the Audit Committee of Central Vietnam Veterinary Products Joint Stock Company I has supervised and monitored the Company's operations in 2025, and hereby reports to the General Meeting of Shareholders on the key contents as follows:

Part I: Summary of the activities of the Audit Committee.

- The Audit Committee has operated according to the Enterprise Law and the Company's Charter, on behalf of the Shareholders to control the production and business activities and management of the Company.

The Audit Committee has assigned specific tasks to each member in each field suitable to their professional qualifications. The members regularly exchange information, work via email, phone, and direct communication, ensuring smooth and timely communication, in line with the Company's operational and production activities

In 2024, the Audit Committee organized 02 meetings regarding the activities of the Audit Committee in the first 6 months of the year and summarized the activities of 2025. The meetings were fully attended by the participating members

The members of the Audit Committee have made efforts to fully participate in all Board of Directors meetings and have also accessed all production and business activities of the Company.

Part II: Remuneration and other benefits of the Audit Committee

The remuneration of the Board of Directors and the Audit Committee for 2025 has been paid in accordance with Resolution No. 18-2025/NQ-ĐHĐCĐ of the General Meeting of Shareholders of the Company, approved on April 26, 2025, and is detailed in the 2025 financial statements, specifically as follows:

Unit of measurement: dong

No.	DESCRIPTION	REMUNERATION AMOUNT AS APPROVED UNDER RESOLUTION NO. 18-2025/NQ-ĐHĐCĐ
1	Nguyen Anh Tuan	36.000.000
2	Nguyen Viet Hoang	24.000.000
3	Phan Quoc Duy	8.000.000
4	Tran Thi Bich Ngoc	16.000.000
	Total	84.000.000

Part III: Results of monitoring the operational and financial situation of the Company

1. Results of production and business activities in 2025 of the Company:

At the end of the 2025 financial year, the Board of Directors directed the Executive Board to prepare the financial report, and the financial report was audited by UHY Audit and Consulting Company Limited. The Supervisory Board agreed with the assessments of the operations and finances in the Company's financial report and the auditing unit with the main indicators as follows:

Results of production and business activities in 2025

Unit: Thousand dong

Financial indicators	Year 2024	Year 2025	% increase/decrease
Net revenue from sales of goods and rendering of services	109.113.684.605	109.113.684.605	15,66%
Operating profit	4.274.591.547	111.692.250.742	2,36%
Net profit before tax	5.093.646.511	8.470.501.184	98,16%
Net profit after tax	3.777.670.212	10.819.960.752	112,42%
Current liabilities	42.042.724.462	8.453.238.318	123,77%
Profit distribution	0%	0%	

(Source: Consolidated audited financial statements for 2025 of Central Vietnam Veterinary Products Joint Stock Company I)

- According to the financial report for 2025 ending on 31/12/2025, the results achieved are as follows:

+ Net revenue from sales and services reached VND 111,692,250,742, achieving 90% of the annual plan.

+ Profit after tax reached VND 8,453,238,318, representing an increase of 65.75% compared to the annual plan.

+ Short-term liabilities decreased to VND 41,127,213,214, down 2.18% compared to the same period of the previous year.

The Audit Committee assesses that the 2025 financial statements have been prepared and presented fairly, in accordance with Vietnamese Accounting Standards and applicable regulations.

No fraud or potential fraud risks were identified in the 2025 financial statements.

2. Transactions with Subsidiaries and Related Parties of the Company

Transactions between Central Vietnam Veterinary Products Joint Stock Company I and its subsidiaries and related parties are conducted in accordance with regulations. The Audit Committee did not detect any abnormalities in these transactions.

Part IV: Results of Monitoring the Board of Directors and Executive Board

- In 2025, the Company's Board of Directors held meetings in person. All meetings were conducted in compliance with the procedures and formalities stipulated in the Charter of Central Vietnam Veterinary Products Joint Stock Company I and the Law on Enterprises.

- Based on the actual situation and the Company's audited financial statements, the Audit Committee has not identified any unusual matters in the Company's management and operational activities.

- The Management has made considerable efforts in operating the Company's production and business activities in line with the directions set by the Board of Directors.

- However, the accumulated losses from previous years continue to pose significant financial pressure on the Company. The Board of Directors and the Management have actively sought solutions to strengthen and restore the market, regain market share through the development of new products and product lines, as well as enhancing product quality and reinforcing connections with the entire customer network.

- The Board of Directors has set the 2026 business plan targets, with net revenue of VND 125,000,000,000 and profit after tax of VND 8,500,000,000, which are considered appropriate in light of the actual situation.

Part V: Results of Evaluating the Internal Control System and Risk Management of the Company, Assessing the Independence and Objectivity of the Independent Audit

The implementation of internal control is well executed, ensuring that business units follow the correct procedures. The Company has issued and strictly implemented internal control and risk management processes in accordance with legal regulations. The selected auditing

company (UHY Auditing and Consulting Company Limited) ensures reliability, honesty, compliance with audit deadlines, adherence to professional regulations, and maintains independence and objectivity when providing audit opinions. The Audit Committee did not detect any issues regarding conflicts of interest, independence, or objectivity of the auditors, the audit team, or the auditing company when conducting audit work.

Part VI: Plan Targets for 2026 and Implementation Solutions of the Audit Committee

I. Current Situation at the Company

- Through the process of reviewing the activities of the entire Company, the Board of Directors and the Audit Committee have agreed to require the branch to complete the tax inspection for all years that have not been inspected to date and prepare all procedures to close the tax code due to the branch's ineffective operation and lack of feasible direction to resolve existing issues.
- At the Ho Chi Minh City branch, the tax debt situation has just been resolved, therefore the tax code closure at the Ho Chi Minh City branch has not yet been implemented

II. Plan targets for 2026:

In 2026, the Company is expected to be significantly affected by economic fluctuations. Based on the revenue and profit achieved in 2025, the Board of Directors has set the 2026 business plan targets at net revenue of VND 125,000,000,000 and profit after tax of VND 8,500,000,000, which are considered appropriate to the actual situation.

However, the Board of Directors should clearly recognize the existing challenges faced by the Company in order to adopt appropriate policies and promptly direct the Management to effectively implement measures to achieve the set objectives.

III. Recommendations and Solutions for implementation in 2025 for the Board of Directors

1. Recommendations:

Based on the actual business situation of 2025, our Audit Committee makes the following recommendations:

The Company needs to continue reviewing and evaluating personnel work, continue restructuring to enhance the operational efficiency of the units.

The Company needs to have a clear direction in its business strategy, consolidate and stabilize what the company already has, serving as a basis and premise for new development, improving and enhancing capacity based on development trends in the specific industry.

2. Solutions:

In 2026, the Company's financial situation has somewhat resolved the difficulties. For the Company to develop, the Audit Committee recommends implementing the following basic solutions:

a. For the office at 88 Truong Chinh:

- The Company's revenue during the year was mainly derived from office leasing. Meanwhile, the number of staff handling the entire workload at the office was only three; therefore, the Board of Directors and the Management should develop plans to strengthen the workforce. The Company should also establish appropriate remuneration policies in line with market benchmarks for each position and overall responsibilities across the system, ensuring alignment with each employee's contributions so that employees can fully utilize their capabilities for the benefit of both the Company and themselves.
- To implement and expand the veterinary pharmaceuticals business at the Company's office in order to generate additional revenue to offset operating costs.

b. For Central Veterinary Company Limited 1

**** With the overall activities of the entire company:***

Although the economy faced many challenges, the Board of Directors and the Management have worked together to set directions for the Company's overall production and business activities; however, the results achieved remain limited.

The Board of Directors and the Management have been making significant efforts to implement Resolution No. 18-2025/NQ-DHĐCĐ of the General Meeting of Shareholders. Accordingly, in 2026, the Company needs to intensify efforts to improve product quality, introduce more products to the market in order to regain market share, increase revenue, and enhance the efficiency of invested capital. At the same time, it is necessary to promptly address and eliminate accumulated losses to deliver greater benefits to the Company's shareholders.

**** With the production and business activities of Veterinary Medicine and Aquaculture:***

Livestock-related diseases continue to develop in a complex manner; therefore, the Company should focus its resources on researching new products suitable for each period and organizing production to ensure timely supply to the market.

The Company should establish appropriate sales and customer care policies to foster close cooperation with customers in business activities, ensuring that all parties are confident in the benefits they receive.

In addition, it is necessary to select personnel with sufficient competence, integrity, and dedication in business operations. At the same time, the Company should implement

appropriate remuneration policies commensurate with each employee's contributions, enabling them to fully utilize their capabilities for the benefit of both the Company and themselves.

Dear Congress, the Audit Committee recognizes that to date, the difficulties of the Company have been somewhat alleviated. If there is effort from the Board of Directors, the Executive Board, the Audit Committee believes that in 2026, the Company will overcome some difficulties, achieve the set goals, and meet the expectations of the shareholders.


Above is the activity report of the Audit Committee of Central Vietnam Veterinary Products Joint Stock Company I in the past period, respectfully submitted to the General Meeting of Shareholders for approval.

The Audit Committee sincerely thanks the esteemed Shareholders

Wishing the congress success./.

ON BEHALF OF THE AUDIT COMMITTEE

Chairman of the Audit Committee



NGUYEN VIET HOANG.

DỰ THẢO

REPORT

ON THE ACTIVITIES OF THE BOARD OF DIRECTORS VIETNAM VETERINARY PRODUCTS JOINT STOCK COMPANY I

Dear General Meeting: First of all, as Chairman of the Board of Directors for the 7th term, I sincerely thank the Shareholders for always supporting and creating all conditions for the Board of Directors and the Executive Board to successfully complete the targets assigned by the General Meeting of Shareholders.

Dear General Meeting: Implementing the Charter on the organization and operation of Central Veterinary products Joint Stock Company I approved by the General Meeting of Shareholders on May 6, 2023; Resolution of the Annual General Meeting of Shareholders in 2025.

On behalf of the Board of Directors, I would like to report to the General Meeting of Shareholders on the activities of the Board of Directors in 2025 and the plan for 2026 as follows:

PART I: ASSESSMENT OF THE COMPANY'S SITUATION IN 2025

1. ABOUT PERSONNEL

In 2025, the personnel situation of the entire Company remains stable, including:

The Board of Directors of Central Veterinary products Joint Stock Company I in 2024 has 3 members including: 01 Chairman of the Board of Directors and 02 members.

The Executive Board includes: The Chairman of the Board of Directors directly manages the departments including: Director, Chief Accountant, Head of Internal Affairs Department and Director of Central Veterinary Company Limited 1

2. ON THE COMPANY'S PRODUCTION AND BUSINESS RESULTS IN 2025

The year 2025 was a challenging one for the global economy, marked by a slowdown in GDP growth, trade, and investment worldwide. Meanwhile, inflation remained at a high level, coupled with escalating geopolitical tensions, increasing technological

fragmentation, and the impacts of extreme weather conditions and widespread disease outbreaks. As a result, the global economic environment has been characterized by rapid, unpredictable changes and a high level of instability. In addition, natural disasters, epidemics, climate change, storms, and droughts have continued to increase risks to global financial and monetary markets, as well as energy and food security. Global economic growth potential is projected to decline to its lowest level in the past three decades.

In this context, the national economy in general and the veterinary pharmaceutical manufacturing sector in particular still experienced certain advantages, especially due to strong demand from the livestock market. However, in 2025, the industry continued to face significant challenges as the prices of animal feed and raw materials—primarily imported—increased compared to the previous year. The continuous rise in input costs has placed considerable pressure on the livestock sector and significantly affected the Company’s production and business operations.

Based on the above advantages and challenges, the production and business performance of Central Veterinary Medicine Joint Stock Company No. 1 in 2025 is as follows:

CONSOLIDATED INCOME STATEMENT 2025

Unit: Thousand Dong			
ITEMS	2023	2025	% increase or decrease
Revenue from sales of goods and rendering of services	112.835.573.099	116.504.435.441	3,25
Operating profit	4.274.591.547	8.470.501.184	98,16
Other expenses	819.054.964	2.349.459.568	186,85
Net profit before tax	5.093.646.511	10.819.960.752	112,42
Net profit after tax	3.777.670.212	8.453.238.318	123,77

(Data from the 2025 financial statements will be presented by the Board of Directors in the financial report).

In 2025, the Company’s production and business activities recorded positive results despite the continued challenges of the economic environment. Specifically, revenue from sales reached VND 116,504,435,441 thousand, an increase of 3.25% compared to 2024. Although revenue growth remained modest, it demonstrates the Company’s ability to maintain operational stability and adapt to market fluctuations.

Notably, profit from operating activities reached VND 8,470,501,184 thousand, a significant increase of 98.16% year-on-year. This reflects improvements in cost management, optimization of production activities, and enhanced profit margins.

In addition, other income amounted to VND 2,349,459,568 thousand, up 186.85%, contributing substantially to total profit. As a result, profit before tax reached VND 10,819,960,752 thousand, up 112.42%, while profit after tax reached VND 8,453,238,318 thousand, an increase of 123.77% compared to 2024.

Overall, 2025 can be considered an effective year of operation for the Company, with strong profit growth despite only modest revenue growth. This outcome indicates improved operational efficiency, effective cost control, and the ability to capitalize on market opportunities. However, revenue growth remains limited; therefore, in the coming period, the Board of Directors should continue to direct efforts toward market expansion, revenue growth, and maintaining cost stability to ensure sustainable development.

In addition to these achievements, the Company still faces certain financial challenges, particularly outstanding payables to suppliers that have not been fully resolved. In recent years, the Board of Directors has implemented various measures to address these issues and gradually stabilize and develop the Company's operations; however, more decisive actions are required in the time ahead.

Accordingly, the Company's production and business results in 2025 were mainly influenced by the following factors:

+ Production and trading activities:

- The Company has proactively sought to expand markets and develop its customer network, contributing to maintaining revenue growth and stabilizing business operations.
- Cost management has been effectively implemented, particularly in controlling production and administrative expenses and optimizing operational processes, thereby significantly improving profit from operating activities.
- Production activities have been enhanced in terms of productivity and product quality, contributing to improved profit margins.
- Other income generated during the year increased substantially, making a significant contribution to the Company's overall profit.
- Demand from the livestock market remained strong, creating favorable conditions for the Company's product consumption.

However, the Company continues to face pressure from rising input costs, particularly imported raw materials, which have affected production costs.

+ Service business performance:

- In 2025, thanks to the efforts of the Board of Directors and the Management in seeking and expanding partnerships, the Company's service business achieved positive results.

Specifically, revenue in 2025 increased by 68.63% compared to 2024, thereby contributing significantly to the growth in profit after tax. Nevertheless, outstanding payables to suppliers have not yet been fully resolved, which continues to exert certain pressure on the Company's financial position and cash flow.

3. Capital and shares situation in 2025:

- Charter capital in 2025: : 162.499.690.000 VND

- Total number of shares : 16.249.969 shares..

Among them

- Number of shares in circulation : 16.249.956 common shares.

- Treasury shares of the Company : 13 shares.

Total number of shareholders as April 14, 2026, : 287 Shareholders

4. Regarding relations with shareholders:

The Company has complied with information disclosure according to the law and applicable legal documents for large-scale public companies and listed organizations. In addition, the relationship with shareholders is maintained regularly and actively through the website and the information disclosure person of the Company.

PART II: ASSESSMENT OF THE OPERATION SITUATION OF THE BOARD OF DIRECTORS

1. Implementation of the Board of Directors' Resolution in 2025

In the context of increasingly intense competition among enterprises in the same industry, alongside efforts to address difficulties and outstanding issues from previous years, the Board of Directors (the "BOD") has proactively directed and managed operations, and mobilized all available resources to maintain and develop the Company's veterinary pharmaceutical production and business activities. At the same time, the Company has continued to strengthen and maintain long-term, sustainable relationships with its customers and partners.

The Board of Directors has implemented the 2025 General Meeting of Shareholders' Resolution through the following key objectives:

1.1. General objectives:

In 2025, the Company continued to uphold and strengthen the reputation of the VINAVETCO brand in the production and trading of veterinary pharmaceuticals, aquaculture products, and vaccines. The Company's operations have been gradually stabilized, aiming toward sustainable development while expanding its market presence across provinces and cities nationwide. In addition, the Company has focused on improving and diversifying its products, enhancing quality, and offering reasonable pricing to meet customer demand.

1.2. Production and business objectives:

- To strengthen the marketing and sales of existing products in the market, while promoting research and development of new products with diverse categories serving

animals, pets, livestock, and poultry. These products include preventive and treatment drugs, antiparasitic medicines, health supplements, growth promoters, reproductive regulators, as well as antifungal and antiparasitic products.

- To ensure sustainable business development, the Board of Directors and the Management have developed a plan to review the entire customer system nationwide, thereby formulating appropriate policies to regain market share, reinforce customer confidence, support distribution agents, and maintain and gradually increase sales revenue.

1.3. Financial objectives:

- To develop monthly, quarterly, and annual financial plans based on consolidated inputs from all departments, ensuring efficient use of the Company's business capital.

- In 2026, the Company plans to establish a Veterinary Diagnostic Center at Central Veterinary Medicine Co., Ltd. No. 1, aiming to expand business operations, enhance resource utilization efficiency, and increase production and business value.

- Since 2022, the Company has engaged UHY Auditing and Consulting Co., Ltd. to conduct audits and reviews of annual financial statements and other reports as required by competent authorities, ensuring compliance with applicable laws and the Company's Charter.

1.4. Human resources objectives:

The Company places strong emphasis on training and development to enhance the quality of its workforce, ensuring both sufficient staffing levels and improved capabilities. At the same time, the Company regularly recruits and supplements experienced personnel, particularly in the business sector, to improve sales performance and overall operational efficiency.

2. Composition of the Board of Directors

The Board of Directors of the Company, from January 1, 2025 to April 26, 2025, comprised three (03) members, of whom:

No.	Name	Title	Position
1	Nguyen Anh Tuan	Chairman of the Board of Directors	Chairman of the BoD – Executive Member
2	Phan Quoc Duy	Commissioner	Non-executive Member of the BoD
3	Nguyen Viet Hoang	Commissioner	Independent Member of the BoD

The Board of Directors of the Company, from April 26, 2025 to December 31, 2025, comprised three (03) members:

No.	Name	Title	Position
1	Nguyen Anh Tuan	Chairman of the Board of Directors	Chairman of the BoD – Executive Member
2	Tran Thi Bich Ngoc	Commissioner	Non-executive Member of the BoD
3	Nguyen Viet Hoang	Commissioner	Independent Member of the BoD

3. Organization of Board of Directors' Meetings

To ensure regular, consistent, and timely implementation of its duties, the Board of Directors of the Company held in-person meetings throughout 2025. All meetings were conducted in compliance with the procedures and formalities stipulated in the Charter of Central Veterinary Medicine Joint Stock Company No. 1 and the Law on Enterprises.

Minutes of the Board of Directors' meetings were duly prepared and signed by all attending members, ensuring compliance with legal requirements in terms of form and content. Relevant documents and materials were provided in full to participating members in advance for review and consideration, in accordance with the Company's Charter. The resolutions issued by the Board of Directors during the year include:

No.	Date	Resolution number	Content	No.
1	02-2025/NQ-HĐQT	15/02/2025	Resolution of the Board of Directors on the development of the 2025 business plan;	100%
2	04-2025/NQ-HĐQT	05/03/2025	Resolution of the Board of Directors on setting the record date for the 2025 General Meeting of Shareholders;	100%
3	05-2025-QĐ-CTHĐQT	05/03/2025	Decision on the establishment of the Organizing Committee for the 2025 General Meeting of Shareholders;	100%
4	07-2025/NQ-HĐQT	01/04/2025	Resolution of the Board of Directors approving reports and documents to be submitted to the 2025 General Meeting of Shareholders;	100%
5	20-2025/NQ-HĐQT	07/06/2025	Resolution of the Board of Directors on reviewing and approving the assignment to Central Veterinary Medicine Co., Ltd. No. 1 to carry out the liquidation of packaging materials and damaged finished goods in accordance with Proposal No. 12-2025/TTr-	100%

No.	Date	Resolution number	Content	No.
			TW1 dated June 6, 2025 of the Director of Central Veterinary Medicine Co., Ltd. No. 1;	
6	21-2025/NQ-HĐQT	26/04/2025	Resolution of the Board of Directors approving the election of additional members of the Audit Committee;	100%
7	22-2025/NQ-HĐQT	02/08/2025	Resolution of the Board of Directors on the results for the first six months of 2025;	100%
8	24-2025/NQ-HĐQT	11/08/2025	Resolution of the Board of Directors on the strategic business alliance with Vietnam Veterinary Pharmaceutical Group Joint Stock Company and Cai Lay Veterinary Pharmaceutical Joint Stock Company;	100%
9	26-2025/NQ-HĐQT	11/09/2025	Resolution of the Board of Directors on the implementation of the fire prevention and fighting system and the liquidation of a generator;	100%
10	27-2025/QĐ-CTHĐQT	24/10/2025	Decision on the liquidation of the generator in accordance with Resolution No. 26-2025/NQ-HĐQT;	100%
11	31-2025/NQ-HĐQT	20/12/2025	Resolution of the Board of Directors on the dismissal and appointment of the Director of Central Veterinary Medicine Co., Ltd. No. 1.	

PHẦN III: BÁO CÁO TÀI CHÍNH NĂM 2025
CONSOLIDATED BALANCE SHEET
As at 31 December 2025


ASSETS	Code	Note	31/12/2025 VND	01/01/2025 VND
CURRENT ASSETS	100		70,321,920,085	59,693,573,390
Cash and cash equivalents	110	4	38,344,430,440	28,209,029,640
Cash	111		13,274,430,440	6,887,029,640
Cash equivalents	112		25,070,000,000	21,322,000,000
Current accounts receivables	130		12,077,864,752	10,252,671,297
Short-term trade receivables	131	7	14,208,700,456	11,501,916,707
Short-term prepayments to suppliers	132	8	808,228,018	1,564,831,000
Other short-term receivables	136	10	4,329,181,817	4,454,169,129
Provision for doubtful short-term receivables	137	11	(7,268,245,539)	(7,268,245,539)
Inventories	140	9	18,818,063,220	19,444,138,888
Inventories	141		18,967,364,495	21,334,861,658
Provision for devaluation of inventories	149		(149,301,275)	(1,890,722,770)
Other current assets	150		1,081,561,673	1,787,733,565
Short-term prepaid expenses	151	5	349,073,963	277,093,435
Value-added tax deductible	152		708,049,710	1,320,066,631
Tax and other receivables from the State budget	153	17	24,438,000	190,573,499
NON-CURRENT ASSETS	200		92,792,288,507	96,082,908,132
Non-current accounts receivables	210		19,965,000	19,965,000
Other long-term receivables	216	10	19,965,000	19,965,000
Fixed assets	220		90,287,772,918	94,731,229,420
Tangible fixed assets	221	12	89,209,084,222	93,532,686,424
- <i>Cost</i>	222		165,909,388,253	165,217,987,866
- <i>Accumulated depreciation</i>	223		(76,700,304,031)	(71,685,301,442)
Intangible fixed assets	227	13	1,078,688,696	1,198,542,996
- <i>Cost</i>	228		2,416,877,460	2,416,877,460
- <i>Accumulated amortization</i>	229		(1,338,188,764)	(1,218,334,464)
Long-term assets in progress	240		324,074,074	-
Construction in progress	242		324,074,074	-
Long-term financial investments	250	6	-	-
Investments in other entities	253		866,640,000	866,640,000
Provision for long-term investments	254		(866,640,000)	(866,640,000)
Other long-term assets	260		2,160,476,515	1,331,713,712
Long-term prepaid expenses	261	5	2,160,476,515	1,331,713,712
TOTAL ASSETS	270		163,114,208,592	155,776,481,522

CONSOLIDATED BALANCE SHEET (CONT'D)

As at 31 December 2025

RESOURCES	Code	Note	31/12/2025 VND	01/01/2025 VND
LIABILITIES	300		53,466,213,214	54,381,724,462
Current liabilities	310		41,127,213,214	42,042,724,462
Short-term trade payables	311	14	22,566,175,583	23,935,611,810
Short-term advances from customers	312		143,476,243	311,292,114
Taxes and other payables to the State budget	313	17	2,401,374,192	1,560,370,236
Payables to employees	314		6,637,863,145	6,393,780,663
Short-term accrued expenses	315	15	3,793,938,088	4,399,433,352
Short-term unearned revenue	318		15,000,000	15,000,000
Other short-term payables	319	16	4,952,779,037	4,738,179,361
Bonus and welfare fund	322		616,606,926	689,056,926
Non-current liabilities	330		12,339,000,000	12,339,000,000
Other long-term payables	337	16	539,000,000	539,000,000
Long-term borrowings and finance lease liabilities	338	18	11,800,000,000	11,800,000,000
OWNERS' EQUITY	400		109,647,995,378	101,394,757,060
Owners' equity	410	19	109,647,995,378	101,394,757,060
Owners' equity	411		162,499,690,000	162,499,690,000
- Shares with voting rights	411a		162,499,690,000	162,499,690,000
Other owners' capital	414		278,962,752	278,962,752
Treasury shares	415		(130,000)	(130,000)
Investment and development	418		3,559,312,727	3,559,312,727
Retained earnings	421		(56,689,840,101)	(64,943,078,419)
- Accumulated retained earnings brought forward	421a		(64,943,078,419)	(68,520,748,631)
- Retained earnings for the current year	421b		8,253,238,318	3,577,670,212
TOTAL RESOURCES	440		163,114,208,592	155,776,481,522

Preparer




Nguyen Thi Phuong

Chief Accountant



Nguyen Thi Thu Ha



Chairman

Nguyen Anh Tuan

CONSOLIDATED INCOME STATEMENT
For the financial year ended 31 December 2025


Items	Code	Note	Year 2025 VND	Year 2024 VND
Revenue from sales of goods and rendering of services	01	21	116,504,435,441	112,835,573,099
Revenue deductions	02	22	4,812,184,699	3,721,888,494
Net revenue from sales of goods and rendering of services	10		111,692,250,742	109,113,684,605
Cost of goods sold and services rendered	11	23	83,160,534,292	81,890,664,520
Gross profit from sales of goods and rendering of services	20		28,531,716,450	27,223,020,085
Financial income	21	24	599,205,099	588,623,333
Financial expenses	22	25	659,506,865	851,079,637
<i>In which: Interest expenses</i>	23		-	-
Selling expenses	25	26	10,161,234,236	12,814,330,333
General and administrative expenses	26	26	9,839,679,264	9,871,641,901
Operating profit	30		8,470,501,184	4,274,591,547
Other income	31	28	2,624,815,364	1,002,070,898
Other expenses	32		275,355,796	183,015,934
Other profit	40		2,349,459,568	819,054,964
Net profit before tax	50		10,819,960,752	5,093,646,511
Current corporate income tax expenses	51	29	2,366,722,434	1,315,976,299
Deferred tax income/(expense)	52		-	-
Net profit after tax	60		8,453,238,318	3,777,670,212
Basis earnings per share	70	30	508	220
Diluted earnings per share	71	31	508	220

Preparer



Nguyen Thi Phuong


Chief Accountant



Nguyen Thi Thu Ha

Hanoi, 25 March 2026

Chairman



Nguyen Anh Tuan

STATEMENT OF THE BOARD OF GENERAL DIRECTORS

The Board of General Directors of Vietnam Veterinary Products Joint Stock Company (hereinafter referred to as “the Company”) presents this report together with the audited consolidated financial statements for the financial year ended 31 December 2025.

BOARD OF MANAGEMENT AND BOARD OF GENERAL DIRECTORS

The members of the Board of Management and the Board of General Directors, who held office during the financial year ended 31 December 2025 and up to the date of this report, include:

Board of Management

Mr. Nguyen Anh Tuan	Chairman of the Board of Management	
Mr. Nguyen Viet Hoang	Member	
Ms. Tran Thi Bich Ngoc	Member	(Appointed on 26 April 2025)
Mr. Phan Quoc Duy	Member	(Resigned on 26 April 2025)

Board of General Directors and Chief Accountant

Ms. Nguyen Thi Thu Hung	Director
Ms. Nguyen Thi Thu Ha	Chief Accountant

SUBSEQUENT EVENTS AFTER THE END OF THE FINANCIAL YEAR

The Company’s Board of General Directors confirms that there have been no significant events occurring after the reporting date which would affect the consolidated financial statements, or require adjustment or disclosure.

THE AUDITOR

The accompanying consolidated financial statements were audited by UHY Auditing and Consulting Company Limited.

THE BOARD OF GENERAL DIRECTORS’ STATEMENT OF RESPONSIBILITY

The Company’s Board of General Directors is responsible for preparing the consolidated financial statements which give a true and fair view of the consolidated financial position of the Company as at 31 December 2025, and of its consolidated results of operation and consolidated cash flows for the financial year ended 31 December 2025, in accordance with Vietnamese Accounting Standards, Vietnamese Corporate Accounting System, and relevant legal regulations on the preparation and presentation of the consolidated financial statements. In preparing these consolidated financial statements, the Board of General Directors is required to:

- Select suitable accounting policies and then apply them consistently;
- Make judgments and estimates that are reasonable and prudent;
- State whether applicable accounting principles have been followed, subject to any material departures disclosed and explained in the consolidated financial statements;
- Prepare the consolidated financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue its business;
- Design and implement an effective system of internal control to ensure preparation and fair presentation of the consolidated financial statements and to mitigate the risks of material misstatement due to fraud or error.

STATEMENT OF THE BOARD OF GENERAL DIRECTORS (CONT'D)

THE BOARD OF GENERAL DIRECTORS' STATEMENT OF RESPONSIBILITY (CONT'D)


The Board of General Directors confirms that the Company has complied with the above requirements in preparing and presenting these consolidated financial statements.

The Board of General Directors is responsible for ensuring that accounting records are properly kept, which disclose, with reasonable accuracy at any time, the financial position of the Company and to ensure that the consolidated financial statements comply with Vietnamese Accounting Standards, Vietnamese Corporate Accounting System and other relevant legal regulations on the preparation and presentation of the consolidated financial statements. It is also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

OTHER COMMITMENTS

The Board of General Directors confirms that the Company has fully complied with its regulatory disclosure obligations as stipulated in Circular No. 96/2020/TT-BTC dated 16 November 2020 of the Ministry of Finance on disclosing information in the Securities Market, as amended and supplemented by Circular No. 68/2024/TT-BTC dated 18 September 2024. Furthermore, The company complies with the regulations in Government Decree No. 155/2020/ND-CP dated 31 December 2020, detailing the implementation of several articles of the Securities Law as amended and supplemented by Decree No. 245/2025/ND-CP dated 11 September 2025, and Circular No. 116/2020/TT-BTC dated 31 December 2020, of the Ministry of Finance guiding several articles on corporate governance applicable to public companies under Decree No. 155/2020/ND-CP.

For and on behalf of the Board of General Directors,



Nguyen Anh Tuan
Chairman of the Board of Management
Hanoi, 25 March 2026

INDEPENDENT AUDITORS' REPORT

*On the consolidated financial statements of Vietnam Veterinary Products Joint Stock Company
For the financial year ended 31 December 2025*

To: Shareholders
The Board of General Directors
Vietnam Veterinary Products Joint Stock Company

We have audited the accompanying consolidated financial statements Vietnam Veterinary Products Joint Stock Company (hereinafter referred to as the "Company") which were prepared on 25 March 2026 as set out on page 06 to 36, comprising the consolidated balance sheet as at 31 December 2025, the consolidated income statement and consolidated cash flow statement for the financial year ended 31 December 2025 and the notes thereto.

The Board of General Directors' responsibility

The Board of General Directors of the Company is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with the Vietnamese Accounting Standards, the Vietnamese Corporate Accounting System and the relevant legal regulations on the preparation and presentation of the consolidated financial statements and for such internal control as the Board of General Directors determines is necessary to enable the preparation and presentation of the consolidated financial statements that are free from material misstatements, whether due to fraud or error.

Responsibilities of the Auditors

Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We conducted our audit in accordance with the Vietnamese Standards on Auditing. Those Standards require that we comply with ethical requirements, plan and perform the audit to obtain reasonable assurance whether the consolidated financial statements are free from material misstatement.


An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The selected procedures depend on the auditor's judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of General Directors, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

INDEPENDENT AUDITORS' REPORT (CONT'D)

Opinion of the Auditors

In our opinion, the accompanying consolidated financial statements give a true and fair view, in all material respects, of the consolidated financial position of the Vietnam Veterinary Products Joint Stock Company as at 31 December 2025 and the consolidated results of its operations and its consolidated cash flows for the financial year then ended, in accordance with Vietnamese Accounting Standards, Vietnamese Corporate Accounting System and relevant legal regulations on the preparation and presentation of the consolidated financial statements.



Nguyen Minh Long
Deputy General Director
Auditor's Practicing Certificate
No. 0666-2023-112-1
For and on behalf of

UHY AUDITING AND CONSULTING COMPANY LIMITED
Hanoi, 25 March 2026

Bui Duc Nam
Auditor
Auditor's Practicing Certificate
No. 5142-2025-112-1



PART IV: PROFIT DISTRIBUTION, REMUNERATION FOR THE BOARD OF DIRECTORS, AUDIT COMMITTEE OF THE COMPANY IN 2024

I. Profit distribution plan

In 2025, the Company recorded a profit after tax of VND 8,253,238,318. However, due to the Company's financial position still reflecting accumulated losses, with total accumulated losses as of December 31, 2025 amounting to VND 56,689,840,101, the Company does not meet the conditions for dividend distribution in accordance with applicable regulations.

Accordingly, the Board of Directors proposes that no dividend be declared or paid for the fiscal year 2025.

II. Remuneration for the Board of Directors and the Audit

Pursuant to the Resolution of the General Meeting of Shareholders in 2025, the Company has implemented the payment of remuneration to the Board of Directors and the Audit Committee in accordance with the approved plan.

Details are as follows:

Unit: VND			
No.	INTERPRETATION	AMOUNT OF REMUNERATION RECEIVED	AMOUNT OF REMUNERATION RECEIVED
1	Board of Directors	84.000.000	84.000.000
	Total	84.000.000	84.000.000

PART V: OPERATIONAL ORIENTATION AND TARGETS FOR 2026

I. Plan and orientation of the Board of Directors

Based on the business performance results in 2025 and the economic outlook for the coming period, the Board of Directors has determined the business plan and strategic orientation for 2026 as follows:

1. General Orientation:

To continue maintaining stable production and business operations, improving operational efficiency and enhancing the Company's competitiveness. The Company will focus on sustainable development through cost optimization, market expansion, and product quality improvement, while maintaining the reputation of the VINAVETCO brand in the veterinary pharmaceutical sector.

2. Production and Business Orientation:

- To promote the consumption of key products while researching and developing new product lines that meet the demands of the livestock and pet markets.

- To expand and strengthen the nationwide distribution network; proactively seek new customers and partners while maintaining long-term relationships with existing clients.
- To enhance the application of science and technology in production in order to improve productivity, product quality, and cost efficiency.

3. Financial Orientation:

- To continue strictly controlling production and administrative expenses to maintain profitability.
- To develop and implement a flexible financial plan to ensure adequate cash flow for business operations.
- To focus on handling and gradually reducing outstanding liabilities, particularly payables to suppliers, in order to improve the Company's financial health.
- Based on the 2025 performance results and the actual business situation, the Board of Directors has agreed on the key targets for the 2026 business plan as follows:

+ Net revenue: **VND 125,000,000,000**

+ Profit after tax: **VND 8,500,000,000**

4. Investment and Development Orientation:

- To implement the plan to establish a Veterinary Diagnostic Center, contributing to business expansion and increasing service value.
- To gradually invest in upgrading facilities and equipment to support production and research and development activities.

5. Human Resources Orientation:

- To continue training and improving professional qualifications and skills for employees.
- To attract and recruit experienced personnel, especially in business and technical fields, to meet the Company's development requirements.

II. Key Targets of the Company

Based on the established plans and orientations, the Board of Directors has identified the key targets for 2026 as follows:

1. General Objectives:

- To maintain and enhance the reputation of the VINAVETCO brand in the production and trading of veterinary medicines, aquaculture products, and vaccines.
- To develop stable and sustainable business operations while expanding the market to provinces and cities nationwide.
- To improve product quality, diversify the product portfolio, and meet customer demand at reasonable prices.

2. Production and Business Objectives:

- To strengthen the consumption of existing products and develop new products for animals, pets, livestock, and poultry, including preventive and treatment drugs, supplements, growth promoters, and anti-parasitic and antifungal products.

- To restore and expand market share by consolidating the existing customer base and seeking new partners and distributors.
- To improve production processes, enhance productivity, and ensure product quality.

3. Financial Objectives:

+ Net revenue: **VND 125,000,000,000**

+ Profit after tax: **VND 8,500,000,000**

To strictly control production and administrative expenses to maintain profitability.

To gradually reduce outstanding liabilities, particularly payables to suppliers, in order to ensure a sound financial position.

4. Human Resources Objectives:

- To provide training and improve the professional qualifications and skills of existing personnel.
- To recruit experienced staff, particularly in sales and technical fields, to support product development and market expansion.

III. Medium- and Long-term Development Strategy

To achieve the stated objectives, the Board of Directors has identified the following key strategies:

1. Market and Customer Strategy:

- To expand into untapped provinces and cities while strengthening relationships with existing customers and long-standing partners.
- To develop a sustainable network of agents and distributors by implementing preferential policies and providing marketing and sales support.
- To enhance customer care capabilities, increase customer loyalty, and optimize the overall customer experience.

2. Product and Innovation Strategy:

- To diversify the product portfolio, including veterinary medicines, aquaculture products, vaccines, and animal healthcare products.
- To promote research and development of new products to meet the increasing demands of the livestock and pet markets.
- To improve product quality, ensuring safety, effectiveness, and competitive pricing.

3. Financial Strategy:

- To control production and administrative costs to ensure profitability and competitiveness.

- To gradually reduce outstanding liabilities, particularly payables to suppliers, in order to maintain stable cash flow and improve financial health.
- To develop flexible financial plans to hedge against market risks and fluctuations in raw material costs.

4. Human Resources Strategy:

- To train and develop the existing workforce, enhancing professional expertise and management skills.
- To recruit experienced personnel, particularly in sales, marketing, and technical fields, to support business expansion.
- To establish incentive policies to retain talent and foster a professional and efficient corporate culture.

5. Governance and Risk Management Strategy:

- To strengthen governance systems and enhance supervision of business operations, ensuring compliance with applicable laws and the Company's internal regulations.
- To establish performance evaluation mechanisms and control risks related to market, financial, operational, and legal aspects.
- To apply information technology in managing production, warehousing, finance, and customer services to improve efficiency and transparency.

IV. Implementation Plan for 2026

To achieve the stated objectives and successfully implement the proposed strategies, the Board of Directors has identified the following key implementation directions:

1. Market and Customer Development:

- To review and classify the existing customer base, thereby developing appropriate support and incentive policies to maintain sales and increase customer loyalty.
- To expand the distribution network in untapped provinces and cities and strengthen connections with strategic partners.
- To organize marketing programs, brand promotion activities, and distributor training to enhance sales effectiveness.

2. Production and Product Development:

- To optimize production processes to improve productivity, reduce costs, and ensure product quality.
- To diversify the product portfolio and promote research and development of new products to meet the needs of the livestock and pet markets.
- To apply strict quality control standards to ensure safety, effectiveness, and brand reputation.

3. Financial Direction:

- To strictly control production and administrative expenses to maintain profitability.
- To develop flexible financial plans to ensure balanced cash flow for business operations.
- To focus on handling and gradually reducing outstanding liabilities, particularly payables to suppliers, in order to improve financial health and mitigate risks.

4. Human Resources Development:

- To organize training programs to enhance the capabilities of employees, particularly in sales, technical, and management fields.
- To recruit experienced personnel to meet the requirements of market expansion and product development.
- To establish incentive and retention policies to attract and retain talent, creating a professional and efficient working environment.

5. Governance and Risk Management:

- To improve the internal governance system and supervise business operations in accordance with transparency and efficiency standards.
- To assess and control risks related to market, finance, products, and legal matters.
- To apply information technology in managing production, warehousing, finance, and customer services to enhance operational efficiency and transparency.

The above presents the Report of the Board of Directors of Central Veterinary products Joint Stock Company I on its performance in 2025 and the plan for 2026. The Board of Directors respectfully submits this report to the General Meeting of Shareholders for consideration and approval.

Thank you very much!

**ON BEHALF OF THE BOARD OF
DIRECTORS**
chairman of the board of directors



NGUYEN ANH TUAN

VIETNAM VETERINARY PRODUCTS JOINT STOCK COMPANY I



Head Office Address: 88 Truong Chinh, Dong Da, Hanoi
Phone Number : 0243.8691262 | Fax: 0243.8691263
Email: info@vinavetco.com | Website: <http://www.vinavetco.com>
Business code : 0100102326

REGULATIONS ON THE ORGANIZATION OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS IN 2026

VIETNAM VETERINARY PRODUCTS JOINT STOCK COMPANY I

- Based on the Enterprise Law No. 59/2020/QH14 dated June 17, 2020;
- Based on the Securities Law No. 54/2019/QH14 dated November 26, 2019;
- Based on Decree 155/2020/ND-CP dated December 31, 2020 and guiding documents;
- Based on the Charter of Organization and Operation of Central Veterinary products Joint Stock Company I.

I. GENERAL PROVISIONS

1. scope of application

- This regulation applies to the organization of the Annual General Meeting of Shareholders in 2026 (hereinafter referred to as the "Meeting") of Central Veterinary products Joint Stock Company I.
- This regulation specifically stipulates the rights and obligations of Shareholders and participants in the Meeting, conditions, and procedures for conducting the Meeting.

2. Conditions for attending the Congress:

the Meeting Shareholders whose names are on the list of Shareholders on the record date for attending the Meeting or authorized representatives of Shareholders.

3. Conditions for conducting the Meeting The

Meeting The Meeting is conducted when the number of shareholders/authorized representatives of shareholders attending the meeting represents over 50% of the total voting shares according to the list of shareholders of the Company established on the record date for the list of shareholders attending the Meeting (May 12, 2026).

II. EXECUTIVE BODY AND ASSISTANCE FOR THE MEETING

The Meeting decides on the number and specific list of the Presidium, Secretariat, Shareholder Qualification Inspection Committee, and Inspection Committee.

1. Presidium

The work of the Meeting is managed by the Presidium elected by the Meeting.

The tasks of the Presidium: Conduct the activities of the Meeting according to the program and regulations approved by the Meeting.

Maintaining the Discussion of Shareholders

Maintain the discussion part of the shareholders. Respond to the issues requested by the Congress. Conclude the issues discussed at the Congress, manage the minutes and resolutions of the Congress.

2. Secretariat

-The Secretariat is the department assisting the Chairman's Delegation, working under the direction of the Chairman's Delegation.

-The tasks of the Secretariat:

Record the minutes of the Congress reflecting the contents and issues mentioned by the Congress. Summarize the discussion opinions at the Congress. Draft the minutes and resolutions of the Congress. Receive and transfer to the Chairman's Delegation the questionnaires/comments from shareholders, documents related to the Congress. Collect, preserve, and send to the Company's Board of Directors the feedback forms from shareholders at the Congress. Other tasks as assigned by the Chairman's Delegation.

3. Ballot Counting Committee

The Ballot Counting Committee is the assisting department of the organizing committee and the Chairman's Delegation, working under the direction of the Chairman's Delegation.

The tasks of the Ballot Counting Committee:

Guide and supervise the voting of shareholders at the Congress. Summarize the number of shares voted on each voting content and announce the voting results before the Congress. Other tasks as assigned by the Chairman's Delegation.

III. RIGHTS AND OBLIGATIONS OF SHAREHOLDERS, AUTHORIZED REPRESENTATIVES OF SHAREHOLDERS

Shareholders and authorized representatives of shareholders have the right to attend, discuss, and vote on all issues within the authority and according to the Program of the Congress.

The Chairman's Delegation will publicly announce the Program of the Congress; the opinions of shareholders and authorized representatives of shareholders at the Congress will be discussed publicly.

At the Congress meeting, shareholders and authorized representatives of shareholders will hear the report contents and the contents presented by the Board of Directors mentioned in

the Program. conference, discussion and approval of each content in the form of voting cards or ballot papers.

Seriously comply with the working regulations of the conference, respect the results of the conference and the management of the Presidium.

IV. INFORMATION AND SPEECH REGIME IN THE CONFERENCE

The Presidium decides on information about the conference, based on compliance with the law and the interests of the Company.

All shareholders have the right to discuss issues related to the agenda of the conference.

Shareholders who wish to discuss at the conference should register their speech content using the shareholder question/comment form provided by the organizing committee and clearly state the discussion issue, sending it to the secretariat for compilation, reporting to the Presidium to organize the discussion of each issue.

Method of speaking: When expressing opinions, shareholders are invited to the podium at the speaking position designated by the Presidium. Shareholders should speak briefly and focus on the key contents that need to be exchanged, in accordance with the registered speech content and the approved conference agenda. The Presidium will arrange for shareholders to speak in the order of registration, while also addressing shareholders' questions. Issues that have been voted on by the conference will not be discussed again. Issues that shareholders registered to discuss but were not addressed within the discussion time according to the approved conference agenda will be considered by the Board of Directors and answered to shareholders in an appropriate manner after the conference.

The Presidium of the conference has the right to remind or request shareholders to focus on the key content that needs to be expressed to save time and ensure the quality of the discussion.

V. PRINCIPLES OF VOTING ON ISSUES AT THE CONFERENCE

Shareholders will vote on issues at the conference using voting cards and ballot papers.

1. Voting Cards; Ballot Papers

Each shareholder is issued a voting card and a ballot paper printed and stamped by the Company.

+ The voting card will be used to collect votes on the following issues:

- Approving the personnel of the Presidium, the Secretariat, the ballot counting -committee;
- Approving the conference agenda, the organization regulations of the conference, the minutes, the resolutions of the conference;
- Other issues within the authority of the general shareholders' meeting (if any).

- For the above matters, shareholders are requested to raise their voting cards high, with the front side indicating the number of shares owned or represented facing the Presidium. Shareholders voting "In favor" shall raise their voting cards first, followed by those voting "Against" or having "No opinion," who shall raise their voting cards subsequently.
- + Ballot papers will be used to collect votes on the following matters:
 - Items included in the agenda of the General Meeting of Shareholders;
 - Other matters within the authority of the General Meeting of Shareholders (if any).

2. Voting Procedures

- + The voting contents recorded on the Voting Card will be voted on by shareholders/authorized representatives of shareholders by choosing the voting opinion "Agree," "Disagree," or "Have no opinion" for each voting content (marking the corresponding voting opinion for each voting content).
- + Shareholders shall cast their votes in accordance with the following principles:
 - Voting shall commence upon the signal of the Presidium of the meeting or the Head of the Vote Counting Committee and shall end when the last shareholder has cast their vote into the ballot box or after 20 minutes from the start of voting, whichever occurs first.
 - Vote counting shall be conducted immediately after the close of voting. Invalid ballot papers include:
 - Ballots not in the prescribed form, not issued by the Company, or not bearing the Company's seal;
 - Ballots that are crossed out, corrected, supplemented, or incorrectly filled in;
 - Ballots that are torn or not intact;
 - Ballots containing additional information or symbols;
 - Ballots not marked in any voting option box and/or marked in two (02) or more boxes for each voting item;
 - Ballots without the signature of the shareholder or the shareholder's authorized representative.
- + Voting for each item on the ballot paper is independent; the validity of the vote for one item does not affect the validity of votes for other items.
- + In case a shareholder makes a mistake while filling in the ballot paper, if the ballot has not yet been submitted to the ballot box and the voting time has not expired, the shareholder may directly contact the Head of the Vote Counting Committee to request a replacement ballot to ensure their rights.
- + The voting results shall be announced by the Vote Counting Committee after consolidating the results for all items in the meeting agenda.

VI. CONDITIONS FOR PASSING THE DECISION OF THE GENERAL MEETING1.

1. One (01) common share is equivalent to one (01) voting right.

2. The following issues are approved when the number of shareholders representing at least 65% of the total voting shares of all attending shareholders agrees: Proposal to amend the charter Amendments and supplements to the contents of the Company Charter; and some issues recorded in Article 21 of the Company Charter.

3. Other resolutions are approved when the number of shareholders owning over 50% (fifty percent) of the total voting shares of all attending shareholders agrees (in the case of holding a direct meeting) or over 50% of the total votes of shareholders with voting rights agree (in the case of collecting opinions from shareholders in writing), except for the cases specified in clauses 3, 4, and 6 of Article 148 of the Enterprise Law.

4. The voting for members of the Board of Directors and the Supervisory Board is conducted by cumulative voting, whereby each shareholder has a total number of voting shares corresponding to the total number of shares owned multiplied by the number of members to be elected of the Board of Directors or the Supervisory Board, and shareholders have the right to allocate all or part of their total votes to one or several candidates. The elected members of the Board of Directors or the Supervisory Board are determined by the number of votes counted from highest to lowest, starting from the candidate with the highest number of votes until the required number of members as stipulated in the Company Charter is reached. In the case of two or more candidates receiving the same number of votes for the last member of the Board of Directors or the Supervisory Board, a re-vote will be conducted among the candidates with the same number of votes or selected according to the election regulations.

5. Other issues under the authority of the General Meeting of Shareholders (if any) in accordance with the provisions of the Enterprise Law and the Charter of organization and operation of the Company.

VII. SOME ISSUES AT THE MEETING

1. Use of mobile phones:

To ensure the meeting is conducted seriously, with quality, and achieves good results, the organizing committee requests that distinguished representatives and shareholders turn off their mobile phones or set them to silent mode. If it is necessary to use the phone, please step outside to talk so as not to affect the meeting.

2. Smoking in the hall:

During the meeting, it is requested that attendees do not smoke in the hall to ensure fire safety and a shared living environment. If any attendees wish to smoke, please do so in designated areas suitable for the benefit of the community.

3. Press and media:

No filming, photography, or recording is allowed without the consent of the Presidium during the meeting.

No information may be transmitted outside in any form until the conclusion of the meeting.

VIII. RESPONSIBILITY FOR IMPLEMENTATION

+ The Presidium, the Secretariat, the Shareholder Eligibility Verification Committee, the Ballot Counting Committee, the delegates, and the shareholders/shareholder representatives must comply with the working regulations of the General Meeting.

+ **Sanctions applied:** In the event that any individual violates these Regulations, they will be expelled from the General Meeting by the Presidium.

IX. MINUTES AND RESOLUTIONS OF THE GENERAL MEETING OF SHAREHOLDERS

All main contents of the General Meeting of Shareholders must be recorded by the Secretary of the Meeting in the minutes of the Meeting. The minutes and resolutions of the General Meeting of Shareholders are to be read and approved before the Meeting is adjourned.

Above is the entire Regulation for organizing the annual General Meeting of Shareholders in 2026 of Central Veterinary products Joint Stock Company I.

Respectfully submitted to the General Meeting of Shareholders for consideration and approval.

**ON BEHALF OF THE BOARD OF
DIRECTORS**
chairman of the board of directors



NGUYEN ANH TUAN



VIETNAM VETERINARY PRODUCTS JOINT STOCK COMPANY I
ANNUAL GENERAL MEETING OF SHAREHOLDERS 2026



VOTING CARD

DELEGATE CODE: VNY.000001

Full name of delegate: NGUYỄN VĂN A

Number of shares owned: 100.000 Share

Number of authorized shares: 0 Share

Number of voting shares: 100.000 Share

Note: This voting card is only valid at the 2026 Annual General Meeting of Shareholders on May 16, 2026 of

Central Veterinary products Joint Stock Company



VIETNAM VETERINARY PRODUCTS JOINT STOCK COMPANY I
ANNUAL GENERAL MEETING OF SHAREHOLDERS 2026

VOTING FORM
SHAREHOLDER CODE: VNY.000001

I. SHAREHOLDER INFORMATION

1. Name of shareholder/Authorized representative: NGUYỄN VĂN A
2. Number of shares owned: 100.000 shares
3. Number of shares authorized: 0 shares
4. **Number of shares entitled to vote: 100.000 shares**

II. OTING CONTENTS

No.	VOTING CONTENT	Opinion		
		Approved	Disapprove	No comments
1	Submission : Report of the Board of Directors			
2	Submission : Approval of the Audit Committee's Report			
3	Submission : Approval of the Audited Financial Report for 2025			
4	Submission : Profit distribution plan for 2025			
5	Submission : Approval of remuneration of the Board of Directors, Audit Committee, and Corporate Governance			
6	Submission : Approval of the Selection of an Audit firm for the 2026 Financial Statements			

Note:

1. Shareholders vote by checking one of the boxes "Agree", "Disagree" or "No opinion" for each voting content.
2. Shareholders must sign and print their full name on the ballot to ensure the validity of the Voting Ballot.
3. This ballot is collected by the Counting Committee and counted at the Congress.

Hung Yen, May 16, 2026
SHAREHOLDER
(Sign and print full name)

(VINAVETCO)

DỰ THẢO

Hưng Yên, May 16, 2026

MINUTES OF VOTE COUNTING

Pursuant to the Charter of Organization and Operation of the Company and Pursuant to the Internal Regulations on the Management of Central Veterinary Medicine Joint Stock Company I approved by the General Meeting of Shareholders.

At 11:30 a.m. on May 16, 2026, at the Hall on the 3rd floor of the Executive Building of Central Veterinary Company Limited 1; Address: At Binh Luong Hamlet, Nhu Quynh Commune, Hung Yen Province

I. Members of the Ballot Counting Committee:

Our Ballot Counting Committee includes:

Ms. Nguyen Thi Thu Ha - Head of the Ballot Counting Committee

Ms. Nguyen Thi Phuong - Member

Mr. Vu Van Don - Member

Ms. Hoang Thi Hang - Member.

The ballots have been counted and approved the contents of the reports and the voting results are as follows:

Number of Delegates participating in the vote: Delegates - In which:

+ Number of Delegates participating directly: Delegates representing shares accounting for ...% of shares with voting rights at the Congress

+ Number of Delegates through proxy:..... Delegates representing shares accounting for ...% of shares with voting rights at the Congress

II. Vote counting results:

+ Total number of ballots issued: Representing: shares, accounting for 100% of the total voting shares.

+ Total number of ballots collected: Representing: shares, accounting for 100% of the total voting shares.

Of which:

- Valid ballots: Representing: shares, accounting for 100% of the total voting shares.
- Invalid ballots: Representing: shares, accounting for% of the total voting shares.
- Unreturned ballots: Representing: shares, accounting for% of the total voting shares.

Vote counting results for each content are as follows:

1. Voting on content 1: Approval of Submission No. 17 - 2026/TTr-DHĐCĐ dated April 16, 2026 of the Board of Directors regarding: Approval of the Report of the Board of Directors.

Voting results:

- Number of shares in favor: shares, representing 100% of the total voting shares at the Meeting;
- Number of shares against: shares, representing% of the total voting shares at the Meeting;
- Number of shares with no opinion: shares, representing% of the total voting shares at the Meeting.

Accordingly, Submission No. 17/2026/TTr-DHĐCĐ dated April 16, 2026 has been approved by the General Meeting of Shareholders with 100% of the total voting shares at the Meeting.

2. Voting on Item 2: Approval of Submission No. 18 - 2026/TTr-DHĐCĐ dated April 16, 2026 of the Board of Directors regarding: Approval of the Audit Committee's Report.

Voting results:

- Number of shares in favor: shares, representing 100% of the total voting shares at the Meeting;
- Number of shares against: shares, representing% of the total voting shares at the Meeting;
- Number of shares with no opinion: shares, representing% of the total voting shares at the Meeting.

Accordingly, Submission No. 18 - 2026/TTr-DHĐCĐ dated April 16, 2026 has been approved by the General Meeting of Shareholders with 100% of the total voting shares at the Meeting.

3. Voting on Item 3: Approval of Submission No. 19 - 2026/TTr-DHĐCĐ dated April 16, 2026 of the Board of Directors regarding: Approval of the audited financial statements for the financial period from January 1, 2025 to December 31, 2025 of

Central Veterinary Products Joint Stock Company I, audited by UHY Auditing and Consulting Co., Ltd., signed on March 25, 2025.

Voting results:

- Number of shares in favor: shares, representing 100% of the total voting shares at the Meeting;
- Number of shares against: shares, representing% of the total voting shares at the Meeting;
- Number of shares with no opinion: shares, representing% of the total voting shares at the Meeting.

Accordingly, Submission No.: 19- 2026/TTr-ĐHĐCĐ dated April 16, 2026 has been approved by the General Meeting of Shareholders with 100% of the total voting shares at the Meeting.

4. Voting on Item 4: Approval of Submission No. 20 - 2026/TTr-ĐHĐCĐ dated April 16, 2026 of the Board of Directors regarding: Approval of profit distribution.

Voting results:

- Number of shares in favor: shares, representing 100% of the total voting shares at the Meeting;
- Number of shares against: shares, representing% of the total voting shares at the Meeting;
- Number of shares with no opinion: shares, representing% of the total voting shares at the Meeting.

Accordingly, Submission No. 20 - 2026/TTr-ĐHĐCĐ dated April 16, 2026 has been approved by the General Meeting of Shareholders with 100% of the total voting shares at the Meeting.

5. Voting on Item 5: Approval of Submission No. 21 - 2026/TTr-ĐHĐCĐ dated April 16, 2026 of the Board of Directors regarding: Approval of the finalization of remuneration for the Board of Directors, the Audit Committee, and the Corporate Governance for 2025, and the proposal for 2026.

Voting results:

- Number of shares in favor: shares, representing 100% of the total voting shares at the Meeting;

- Number of shares against: shares, representing% of the total voting shares at the Meeting;
- Number of shares with no opinion: shares, representing% of the total voting shares at the Meeting.

Accordingly, Submission No. 21 - 2026/TTr-ĐHĐCĐ dated April 16, 2026 has been approved by the General Meeting of Shareholders with 100% of the total voting shares at the Meeting.

6. Voting on Item 6: Approval of Submission No. 22- 2026/TTr-ĐHĐCĐ dated April 16, 2026 of the Audit Committee regarding: Approval of the selection of the auditing firm for 2026.

Voting results:

- Number of shares in favor: shares, representing 100% of the total voting shares at the Meeting;
- Number of shares against: shares, representing% of the total voting shares at the Meeting;
- Number of shares with no opinion: shares, representing% of the total voting shares at the Meeting.

Accordingly, Submission No. 22 - 2026/TTr-ĐHĐCĐ dated April 16, 2026 has been approved by the General Meeting of Shareholders with 100% of the total voting shares at the Meeting.

The vote counting minutes consist of 04 pages, completed at 11:30 on May 16, 2026 and have been publicly approved before the Congress.

HEAD OF THE BALL COUNTING COMMITTEE


Nguyen Thi Thu Ha

MEMBER OF THE BALL COUNTING COMMITTEE

Nguyen Thi Phuong

Vu Van Don

Hoang Thi Hang



No : 23 - 2026/BB - ĐHĐCĐ

Hung Yen, May 16, 2026



REPORT
ANNUAL GENERAL MEETING OF SHAREHOLDERS 2026
Vietnam Veterinary Products Joint Stock Company I

Company Name : Vietnam Veterinary Products Joint Stock Company I

Address: 88 Truong Chinh Street, Kim Lien Ward, Hanoi City.

Business Registration Certificate No : 0100102326 issued by Hanoi Department of Planning and Investment on June 7, 2000 (Amended for the 16th time on July 14, 2025.)

Time to welcome and check shareholder status: From 7:30 to 8:00 Saturday, May 16, 2026

Venue of the Congress: Central Veterinary Company Limited 1: At Binh Luong Hamlet, Nhu Quynh Commune, Hung Yen Province

Participants: Board of Directors (BOD), Audit Committee (UBKT),
Shareholders/Shareholder representatives of Central Veterinary Products Joint Stock Company I.

PART I: INTRODUCTION OPENING OF THE GENERAL MEETING

I. Report on shareholder qualification verification:

+ Reporter: Ms. Hoang Thi Hang - Shareholder Qualification Inspection Committee

+ Report content:

+ The total number of existing shareholders of the Company as recorded by Vietnam Securities Depository and Clearing Corporation (VSDC) As of April 14, 2026 owns 16,249,956 voting shares of Central Veterinary Products Joint Stock Company I

+ There were shareholders and authorized representatives attending the Meeting, representing voting shares, accounting for% of the total number of voting shares.

+ According to the Law on Enterprises and the Company's Charter, the Annual General Meeting of Shareholders held on May 16, 2026 of Central Veterinary Products Joint Stock Company I is eligible to hold the General Meeting.

+ Each share equals one vote. The total number of votes at the meeting is representing% of total voting shares.

II. Approval of the Working Regulations of the Congress, Introduction and approval of the Presidium, Secretary, and Ballot Counting Committee.

For the Congress to proceed, Ms. Hoang Thi Hang - after being authorized by the Board of Directors and the Presidium, read the Working Regulations of the Congress and introduced the Presidium, Secretariat, and Ballot Counting Committee of the Congress. At the Congress, the following items were approved by raising voting cards:

1. Approval of the Working Regulations of the 2026 Annual General Meeting of Shareholders of Central Veterinary Products Joint Stock Company I:

Total number of votes in favor: votes, accounting for 100% of the votes at the General Meeting;

Total number of votes against: 0 votes, accounting for 0% of the total votes at the General Meeting;

Total number of votes with no opinion: 0 votes, accounting for 0% of the total votes at the General Meeting.

Based on the Charter of Central Veterinary Products Joint Stock Company I, the content was approved with 100% of the total votes at the General Meeting.

2. Through the members of the Presidium of the Congress:

Mr. Nguyen Anh Tuan - Chairman of the Board of Directors - Chairman of the Congress

Mr. Nguyen Viet Hoang - Independent Member of the Board of Directors

Ms. Tran Thi Bich Ngoc – Member of the Board of Directors.

Total number of votes in favor: votes, accounting for 100% of the votes at the Congress;

Total number of votes against: 0 votes, accounting for 0% of the total votes at the Congress;

Total number of votes with no opinion: 0 votes, accounting for 0% of the total votes at the Congress.

Pursuant to the Charter of Central Veterinary Products Joint Stock Company I, the content was approved with 100% of the total votes at the Congress.

3. Through the members of the Congress Secretariat:

Ms.: Nguyen Thi Thanh Binh - Head of the Secretariat

Ms.: Dao Thu Trang - Member

Total number of votes in favor: votes, accounting for 100% of the votes at the Congress;

Total number of votes against: 0 votes, accounting for 0% of the total votes at the Congress;

Total number of votes with no opinion: 0 votes, accounting for 0% of the total votes at the Congress.

Based on the Charter of Central Veterinary Products Joint Stock Company I, the content was approved with 100% of the total votes at the Congress.

4. Through the members of the Congress Ballot Counting Committee:

Ms. Nguyen Thi Thu Ha - Head of the Ballot Counting Committee

Ms. Nguyen Thi Phuong - Member

Mr. Vu Van Don - Member

Ms. Hoang Thi Hang - Member.

Total number of votes in favor:votes, accounting for 100% of the votes at the Congress;

Total number of votes against: 0 votes, accounting for 0% of the total votes at the Congress;

Total number of votes with no opinion: 0 votes, accounting for 0% of the total votes at the Congress.

Pursuant to the Charter of Central Veterinary Products Joint Stock Company I, the content was approved with 100% of the total votes at the Congress.

III. Approval of the Meeting Agenda

As of 8:30 a.m., prior to voting at the General Meeting, the number of shareholders and authorized representatives attending the Meeting was shareholders, holding and representing shares, equivalent to voting rights at the Meeting, accounting for% of the total voting rights of the Company.

The Chairperson of the Meeting approved the agenda of the 2026 Annual General Meeting of Shareholders (the Meeting adopted it by a show of voting cards):

Total number of votes in favor: 11,795,032 shares, accounting for 100% of the votes at the General Meeting;

Total number of votes against: 0 votes, accounting for 0% of the total votes at the General Meeting;

Total number of votes with no opinion: 0 votes, accounting for 0% of the total votes at the General Meeting.

Based on the Charter of Central Veterinary Products Joint Stock Company I, the content was approved with 100% of the total votes at the General Meeting.

PART II: CONFERENCE CONTENT

2.1. At the Congress, the members of the Presidium presented reports and proposals, specifically as follows:

1. Report on the activities of the Board of Directors in 2025 and its orientations for 2026.
2. Report on the activities of the Audit Committee in 2025 and its action plan for 2026.
3. Proposal for approval of the Report on the activities of the Board of Directors in 2025 and its orientations for 2026.
4. Proposal for approval of the Report on the activities of the Audit Committee in 2025 and its action plan for 2026.
5. Proposal for approval of the Financial Statements for the fiscal year from January 1, 2025 to December 31, 2025 of Central Veterinary Medicine Joint Stock Company No. 1, audited by UHY Auditing and Consulting Co., Ltd., with the audit report dated March 25, 2026.
6. Proposal on the profit distribution plan for 2025 and the business plan for 2026.
7. Proposal on the approval of the finalization of remuneration for the Board of Directors and the Audit Committee in 2025, and the proposed remuneration for members of the Board of Directors, the Audit Committee and Corporate Governance for 2026.
8. Proposal on the selection of the auditing firm for the fiscal year 2026.

PART III: DISCUSSION:

All shareholders unanimously approved and raised no further comments.

PART IV: SHAREHOLDER VOTING

After listening to the contents of the reports and proposals, the Congress discussed and voted unanimously to pass the resolution. The voting results of the contents of the Congress were recorded in the minutes of the vote counting prepared by the Ballot Counting Committee and read by Ms. Nguyen Thi Thu Ha - Head of the Ballot Counting Committee to the entire Congress, with the following contents:

1. Approval of Proposal No. 17-2026/TTr-ĐHĐCĐ dated April 16, 2026 regarding the Report on the activities of the Board of Directors in 2025 and orientations for 2026

Total number of ballots issued:, representing voting rights, accounting for 100% of the total voting rights at the Meeting.

Total number of ballots collected:, representing voting rights, accounting for 100% of the total voting rights at the Meeting, of which:

+ Valid ballots:, representing voting rights, accounting for 100% of the total voting rights at the Meeting;

+ Invalid ballots: 0, representing 0 voting rights, accounting for 0% of the total voting rights at the Meeting.

Voting results are as follows:

Total votes in favor: votes, representing 100% of the total voting rights at the Meeting;

Total votes against: 0 votes, representing 0% of the total voting rights at the Meeting;

Total abstentions: 0 votes, representing 0% of the total voting rights at the Meeting.

Pursuant to the Charter of Central Veterinary Products Joint Stock Company I, Proposal No. 17-2026/TTr-ĐHĐCĐ dated April 16, 2026 has been duly approved with 100% of the total voting rights at the Meeting.

2. Approval of Proposal No. 18-2026/TTr-ĐHĐCĐ dated April 16, 2026 regarding the Report on the activities of the Audit Committee in 2025 and its action plan for 2026

Total number of ballots issued:, representing voting rights, accounting for 100% of the total voting rights at the Meeting.

Total number of ballots collected:, representing voting rights, accounting for 100% of the total voting rights at the Meeting, of which:

+ Valid ballots:, representing voting rights, accounting for 100% of the total voting rights at the Meeting;

+ Invalid ballots: 0, representing 0 voting rights, accounting for 0% of the total voting rights at the Meeting.

Voting results are as follows:

Total votes in favor: votes, representing 100% of the total voting rights at the Meeting;

Total votes against: 0 votes, representing 0% of the total voting rights at the Meeting;

Total abstentions: 0 votes, representing 0% of the total voting rights at the Meeting.

Pursuant to the Charter of Central Veterinary Products Joint Stock Company I, Proposal No. 18-2026/TTr-ĐHĐCĐ dated April 16, 2026 has been duly approved with 100% of the total voting rights at the Meeting.

3. Approval of Proposal No. 19-2026/TTr-ĐHĐCĐ dated April 16, 2026 regarding the Financial Statements for the fiscal period from January 1, 2025 to December 31, 2025 of Central Veterinary Products Joint Stock Company I, audited by UHY Auditing and Consulting Company Limited and signed on March 25, 2026

Total number of ballots issued:, representing voting rights, accounting for 100% of the total voting rights at the Meeting.

Total number of ballots collected:, representing voting rights, accounting for 100% of the total voting rights at the Meeting, of which:

+ Valid ballots:, representing voting rights, accounting for 100% of the total voting rights at the Meeting;

+ Invalid ballots: 0, representing 0 voting rights, accounting for 0% of the total voting rights at the Meeting.

Voting results are as follows:

Total votes in favor: votes, representing 100% of the total voting rights at the Meeting;

Total votes against: 0 votes, representing 0% of the total voting rights at the Meeting;
Total abstentions: 0 votes, representing 0% of the total voting rights at the Meeting.

Pursuant to the Charter of Central Veterinary Products Joint Stock Company I, Proposal No. 19-2026/TTr-ĐHĐCĐ dated April 16, 2026 has been duly approved with 100% of the total voting rights at the Meeting.

4. Approval of Proposal No. 20-2026/TTr-ĐHĐCĐ dated April 16, 2026 regarding the profit distribution plan for 2025 and the business plan for 2026

Total number of ballots issued:, representing voting rights, accounting for 100% of the total voting rights at the Meeting.

Total number of ballots collected:, representing voting rights, accounting for 100% of the total voting rights at the Meeting, of which:

+ Valid ballots:, representing voting rights, accounting for 100% of the total voting rights at the Meeting;

+ Invalid ballots: 0, representing 0 voting rights, accounting for 0% of the total voting rights at the Meeting.

Voting results are as follows:

Total votes in favor: votes, representing 100% of the total voting rights at the Meeting;

Total votes against: 0 votes, representing 0% of the total voting rights at the Meeting;

Total abstentions: 0 votes, representing 0% of the total voting rights at the Meeting.

Pursuant to the Charter of Central Veterinary Products Joint Stock Company I, Proposal No. 20 -2026/TTr-ĐHĐCĐ dated April 16, 2026 has been duly approved with 100% of the total voting rights at the Meeting.

5. Approval of Proposal No. 21-2026/TTr-ĐHĐCĐ dated April 16, 2026 regarding the approval of the finalization of remuneration for the Board of Directors, the Audit Committee and Corporate Governance in 2025, and the proposed remuneration for members of the Board of Directors, the Audit Committee and Corporate Governance for 2026

Total number of ballots issued:, representing voting rights, accounting for 100% of the total voting rights at the Meeting.

Total number of ballots collected:, representing voting rights, accounting for 100% of the total voting rights at the Meeting, of which:

+ Valid ballots:, representing voting rights, accounting for 100% of the total voting rights at the Meeting;

+ Invalid ballots: 0, representing 0 voting rights, accounting for 0% of the total voting rights at the Meeting.

Voting results are as follows:

Total votes in favor: votes, representing 100% of the total voting rights at the Meeting;

Total votes against: 0 votes, representing 0% of the total voting rights at the Meeting;

Total abstentions: 0 votes, representing 0% of the total voting rights at the Meeting.

Pursuant to the Charter of Central Veterinary Products Joint Stock Company I, Proposal No. 21 -2026/TTr-ĐHĐCĐ dated April 16, 2026 has been duly approved with 100% of the total voting rights at the Meeting.

6. Approval of Proposal No. 22-2026/TTr-ĐHĐCĐ dated April 16, 2026 regarding the selection of the auditing firm for the fiscal year 2026

Total number of ballots issued:, representing voting rights, accounting for 100% of the total voting rights at the Meeting.

Total number of ballots collected:, representing voting rights, accounting for 100% of the total voting rights at the Meeting, of which:

+ Valid ballots:, representing voting rights, accounting for 100% of the total voting rights at the Meeting;

+ Invalid ballots: 0, representing 0 voting rights, accounting for 0% of the total voting rights at the Meeting.

Voting results are as follows:

Total votes in favor: votes, representing 100% of the total voting rights at the Meeting;

Total votes against: 0 votes, representing 0% of the total voting rights at the Meeting;

Total abstentions: 0 votes, representing 0% of the total voting rights at the Meeting.

Pursuant to the Charter of Central Veterinary Products Joint Stock Company I, Proposal No. 22 -2026/TTr-ĐHĐCĐ dated April 16, 2026 has been duly approved with 100% of the total voting rights at the Meeting.

PART V: APPROVAL OF THE MEETING MINUTES

Presented by: Ms. Nguyen Thi Thanh Binh – Head of the Meeting Secretariat, who read out the Minutes of the Meeting.

The General Meeting unanimously approved the full text of the Minutes of the Annual General Meeting of Shareholders dated May 16, 2026 with 100% of votes in favor.

This Minutes is made in 04 copies and is kept at Central Veterinary Products Joint Stock Company I.

The meeting ended at 11:30 a.m. on the same day.

**HEAD OF THE GENERAL
MEETING SECRETARY**

**CHAIRPERSON OF THE GENERAL
MEETING**

Nguyen Thi Thanh Binh

Nguyen Anh Tuan

DỰ THẢO

No: 24 - 2026/NQ - ĐHĐCĐ

Hung Yen, May 16, 2026

RESOLUTION
ANNUAL GENERAL MEETING OF SHAREHOLDERS 2026
Vietnam Veterinary Products Joint Stock Company I

- Pursuant to Law on Enterprises No. 59/2020/QH14 dated June 17, 2020;
- Pursuant to the Securities Law No. 54/2019/QH14 passed by the National Assembly of the Socialist Republic of Vietnam on November 26, 2019 and guiding documents;
- Pursuant to the Charter of organization and operation of Central Veterinary Products Joint Stock Company I;
- Pursuant to the Minutes of the 2025 Annual General Meeting of Shareholders No. 23 - 2026/BB-ĐHĐCĐ dated May 16, 2026 of Central Veterinary Products Joint Stock Company I,

RESOLUTION:

Article 1: Approval of the following contents:

1. Approval of the Report of the Board of Directors;
2. Approval of the Audit Committee's Report;
3. Approval of the Audited Financial Statement for the fiscal period from January 1, 2025 to December 31, 2025 of Central Veterinary Products Joint Stock Company I prepared by UHY Auditing and Consulting LLC and signed on March 25, 2026;
4. Approval of the Proposal on the profit distribution plan for 2025 and the projected profit distribution plan for 2026;
5. Approval of the Proposal on the finalization of remuneration for the Board of Directors, the Audit Committee and Corporate Governance in 2025, and the proposed remuneration for members of the Board of Directors, the Audit Committee and Corporate Governance for 2026;
6. Approval of the Proposal on the selection of the auditing firm for the fiscal year 2026. The General Meeting of Shareholders authorizes the Audit Committee to select an auditing firm from the list of independent auditing firms eligible under applicable regulations to audit the semi-annual financial statements for 2026 and the annual financial statements for 2026 (and to review quarterly financial statements if required by competent state authorities).



Article 2: This Resolution was fully adopted by the 2026 Annual General Meeting of Shareholders of Central Veterinary Products Joint Stock Company I at the Meeting. The Board of Directors and the Management are responsible for the implementation of this Resolution.

This Resolution shall take effect from the date of signing.

Recipients:

- *Shareholders*
- *Board of Directors, Audit Committee, Board of Management, Company Secretary;*
- *Archive;*

**CENTRAL VIETNAM VETERINARY
PRODUCTS JOINT STOCK COMPANY I
FOR AND ON BEHALF OF THE GENERAL
MEETING OF SHAREHOLDERS**

Nguyen Anh Tuan

